RACIAL AND SOCIOECONOMIC EQUITY OF TECOVIRIMAT TREATMENT DURING THE 2022 MPOX EMERGENCY, NEW YORK, NEW YORK, USA

Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA

Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA

Blog Article

We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox Menopause Support emergency; 32.4% received tecovirimat.Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.

0% (Hispanic/Latino), and 30.1% Electronic Board (Asian/Pacific Islander/other).Future public health emergency responses must prioritize institutional and structural racism mitigation.

Report this page